Bharat Biotech inks pact with Washington University's School of Medicine for COVID-19 vaccine

The company envisions to scale this vaccine to one billion doses, translating to an equal number of individuals vaccinated receiving a single-dose regimen.

Published: 23rd September 2020 01:07 PM  |   Last Updated: 24th September 2020 07:45 AM   |  A+A-

Coronavirus Vaccine

For representational purposes. (Photo | AP)

By Express News Service

HYDERABAD: Hyderabad-based vaccine manufacturer Bharat Biotech on Wednesday announced a licensing agreement with the Washington University School of Medicine in St. Louis, USA, for developing a single-dose intranasal vaccine for Covid-19. 

The vaccine is based on a novel chimp-adenovirus and its phase-1 trials will take place at the university’s Vaccine and Treatment Evaluation Unit, according to a press release issued by the company. 

After obtaining necessary approvals from the Indian authorities, further stages of the clinical trial will take place in the country and large-scale manufacturing will begin at the company’s facility in Genome Valley, Hyderabad.

Bharat Biotech will own the rights to distribute the vaccine in all countries, barring the USA, Japan and Europe, and aims to manufacture up to one billion doses. This will help an equal number of people as the vaccine is a single dose. 

“An intranasal vaccine will not only be simple to administer but also reduce the use of medical consumables such as needles and syringes. This will significantly bring down the overall cost of a vaccination drive,” Bharat Biotech chairman and managing director Dr Krishna Ella said. He added, “Our experience in viral vaccines, manufacturing capabilities and distribution continues to be our strong suit, especially in ensuring safe, efficacious and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine to fight Covid-19 across the world”.

The company claims that the vaccine has already shown unprecedented levels of protection in mice and data from the study was recently published in the journal, Cell. Dr David T Curiel, director of the Biologic Therapeutics Center at the Washington University School of Medicine and interim CEO of Precision Virologics, said, “The ability to accomplish effective immunisation with a single nasal dose is a major advantage, offering broader reach and easier administration. An effective nasal dose not only protects against Covid-19, but also prevents the spread of the disease by offering another kind of immunity which occurs primarily in the cells that line the nose and throat. Most other vaccine candidates, currently under development, cannot do that”.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp